company background image
ALPIX logo

Pixium Vision ENXTPA:ALPIX Stock Report

Last Price

€0.38

Market Cap

€1.5m

7D

0%

1Y

-86.3%

Updated

07 Mar, 2024

Data

Company Financials

ALPIX Stock Overview

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. More details

ALPIX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Pixium Vision SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pixium Vision
Historical stock prices
Current Share Price€0.38
52 Week High€9.55
52 Week Low€0.071
Beta0.95
1 Month Change0%
3 Month Change401.87%
1 Year Change-86.34%
3 Year Change-99.59%
5 Year Change-99.54%
Change since IPO-99.91%

Recent News & Updates

Recent updates

Pixium Vision (EPA:ALPIX) Has Debt But No Earnings; Should You Worry?

Mar 01
Pixium Vision (EPA:ALPIX) Has Debt But No Earnings; Should You Worry?

Reflecting on Pixium Vision's (EPA:ALPIX) Share Price Returns Over The Last Five Years

Jan 07
Reflecting on Pixium Vision's (EPA:ALPIX) Share Price Returns Over The Last Five Years

Shareholder Returns

ALPIXFR Medical EquipmentFR Market
7D0%0.2%-1.8%
1Y-86.3%24.3%-4.9%

Return vs Industry: ALPIX underperformed the French Medical Equipment industry which returned 22.6% over the past year.

Return vs Market: ALPIX underperformed the French Market which returned 5.5% over the past year.

Price Volatility

Is ALPIX's price volatile compared to industry and market?
ALPIX volatility
ALPIX Average Weekly Movement74.3%
Medical Equipment Industry Average Movement6.6%
Market Average Movement4.5%
10% most volatile stocks in FR Market9.5%
10% least volatile stocks in FR Market2.3%

Stable Share Price: ALPIX's share price has been volatile over the past 3 months.

Volatility Over Time: ALPIX's weekly volatility has increased from 69% to 74% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201140Lloyd Diamondwww.pixium-vision.com

Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat blindness, which replace the normal physiological function of the eye’s photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the stimulation to the brain via the intermediary of the optic nerve. The company has collaboration agreements with Stanford University in California, Institute of Ocular Microsurgery in Barcelona, Institut de la Vision in Paris, Moorfields Eye Hospital in London, University Hospital in Bonn, and UPMC in Pittsburgh.

Pixium Vision SA Fundamentals Summary

How do Pixium Vision's earnings and revenue compare to its market cap?
ALPIX fundamental statistics
Market cap€1.53m
Earnings (TTM)-€10.52m
Revenue (TTM)€1.80m

0.9x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALPIX income statement (TTM)
Revenue€1.80m
Cost of Revenue€0
Gross Profit€1.80m
Other Expenses€12.32m
Earnings-€10.52m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.58
Gross Margin100.00%
Net Profit Margin-584.66%
Debt/Equity Ratio-127.5%

How did ALPIX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/07 07:02
End of Day Share Price 2024/03/07 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pixium Vision SA is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBrookline Capital Markets
Hugo SolvetBryan Garnier & Co
Pooya HemamiEdison Investment Research